Cargando…

Porphyrin Based 2D-MOF Structures as Dual-Kinetic Sorafenib Nanocarriers for Hepatoma Treatment

The existing clinical protocols of hepatoma treatment require improvement of drug efficacy that can be achieved by harnessing nanomedicine. Porphyrin-based, paddle-wheel framework (PPF) structures were obtained and tested as dual-kinetic Sorafenib (SOR) nanocarriers against hepatoma. We experimental...

Descripción completa

Detalles Bibliográficos
Autores principales: Bieniek, Adam, Wiśniewski, Marek, Czarnecka, Joanna, Wierzbicki, Jędrzej, Ziętek, Marcin, Nowacki, Maciej, Grzanka, Dariusz, Kloskowski, Tomasz, Roszek, Katarzyna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8536990/
https://www.ncbi.nlm.nih.gov/pubmed/34681820
http://dx.doi.org/10.3390/ijms222011161
_version_ 1784588141208797184
author Bieniek, Adam
Wiśniewski, Marek
Czarnecka, Joanna
Wierzbicki, Jędrzej
Ziętek, Marcin
Nowacki, Maciej
Grzanka, Dariusz
Kloskowski, Tomasz
Roszek, Katarzyna
author_facet Bieniek, Adam
Wiśniewski, Marek
Czarnecka, Joanna
Wierzbicki, Jędrzej
Ziętek, Marcin
Nowacki, Maciej
Grzanka, Dariusz
Kloskowski, Tomasz
Roszek, Katarzyna
author_sort Bieniek, Adam
collection PubMed
description The existing clinical protocols of hepatoma treatment require improvement of drug efficacy that can be achieved by harnessing nanomedicine. Porphyrin-based, paddle-wheel framework (PPF) structures were obtained and tested as dual-kinetic Sorafenib (SOR) nanocarriers against hepatoma. We experimentally proved that sloughing of PPF structures combined with gradual dissolving are effective mechanisms for releasing the drug from the nanocarrier. By controlling the PPF degradation and size of adsorbed SOR deposits, we were able to augment SOR anticancer effects, both in vitro and in vivo, due to the dual kinetic behavior of SOR@PPF. Obtained drug delivery systems with slow and fast release of SOR influenced effectively, although in a different way, the cancer cells proliferation (reflected with EC50 and ERK 1/2 phosphorylation level). The in vivo studies proved that fast-released SOR@PPF reduces the tumor size considerably, while the slow-released SOR@PPF much better prevents from lymph nodes involvement and distant metastases.
format Online
Article
Text
id pubmed-8536990
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-85369902021-10-24 Porphyrin Based 2D-MOF Structures as Dual-Kinetic Sorafenib Nanocarriers for Hepatoma Treatment Bieniek, Adam Wiśniewski, Marek Czarnecka, Joanna Wierzbicki, Jędrzej Ziętek, Marcin Nowacki, Maciej Grzanka, Dariusz Kloskowski, Tomasz Roszek, Katarzyna Int J Mol Sci Article The existing clinical protocols of hepatoma treatment require improvement of drug efficacy that can be achieved by harnessing nanomedicine. Porphyrin-based, paddle-wheel framework (PPF) structures were obtained and tested as dual-kinetic Sorafenib (SOR) nanocarriers against hepatoma. We experimentally proved that sloughing of PPF structures combined with gradual dissolving are effective mechanisms for releasing the drug from the nanocarrier. By controlling the PPF degradation and size of adsorbed SOR deposits, we were able to augment SOR anticancer effects, both in vitro and in vivo, due to the dual kinetic behavior of SOR@PPF. Obtained drug delivery systems with slow and fast release of SOR influenced effectively, although in a different way, the cancer cells proliferation (reflected with EC50 and ERK 1/2 phosphorylation level). The in vivo studies proved that fast-released SOR@PPF reduces the tumor size considerably, while the slow-released SOR@PPF much better prevents from lymph nodes involvement and distant metastases. MDPI 2021-10-16 /pmc/articles/PMC8536990/ /pubmed/34681820 http://dx.doi.org/10.3390/ijms222011161 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Bieniek, Adam
Wiśniewski, Marek
Czarnecka, Joanna
Wierzbicki, Jędrzej
Ziętek, Marcin
Nowacki, Maciej
Grzanka, Dariusz
Kloskowski, Tomasz
Roszek, Katarzyna
Porphyrin Based 2D-MOF Structures as Dual-Kinetic Sorafenib Nanocarriers for Hepatoma Treatment
title Porphyrin Based 2D-MOF Structures as Dual-Kinetic Sorafenib Nanocarriers for Hepatoma Treatment
title_full Porphyrin Based 2D-MOF Structures as Dual-Kinetic Sorafenib Nanocarriers for Hepatoma Treatment
title_fullStr Porphyrin Based 2D-MOF Structures as Dual-Kinetic Sorafenib Nanocarriers for Hepatoma Treatment
title_full_unstemmed Porphyrin Based 2D-MOF Structures as Dual-Kinetic Sorafenib Nanocarriers for Hepatoma Treatment
title_short Porphyrin Based 2D-MOF Structures as Dual-Kinetic Sorafenib Nanocarriers for Hepatoma Treatment
title_sort porphyrin based 2d-mof structures as dual-kinetic sorafenib nanocarriers for hepatoma treatment
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8536990/
https://www.ncbi.nlm.nih.gov/pubmed/34681820
http://dx.doi.org/10.3390/ijms222011161
work_keys_str_mv AT bieniekadam porphyrinbased2dmofstructuresasdualkineticsorafenibnanocarriersforhepatomatreatment
AT wisniewskimarek porphyrinbased2dmofstructuresasdualkineticsorafenibnanocarriersforhepatomatreatment
AT czarneckajoanna porphyrinbased2dmofstructuresasdualkineticsorafenibnanocarriersforhepatomatreatment
AT wierzbickijedrzej porphyrinbased2dmofstructuresasdualkineticsorafenibnanocarriersforhepatomatreatment
AT zietekmarcin porphyrinbased2dmofstructuresasdualkineticsorafenibnanocarriersforhepatomatreatment
AT nowackimaciej porphyrinbased2dmofstructuresasdualkineticsorafenibnanocarriersforhepatomatreatment
AT grzankadariusz porphyrinbased2dmofstructuresasdualkineticsorafenibnanocarriersforhepatomatreatment
AT kloskowskitomasz porphyrinbased2dmofstructuresasdualkineticsorafenibnanocarriersforhepatomatreatment
AT roszekkatarzyna porphyrinbased2dmofstructuresasdualkineticsorafenibnanocarriersforhepatomatreatment